CervoMed Inc
CRVO
Company Profile
Business description
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Contact
20 Park Plaza
Suite 424
BostonMA02116
USAT: +1 617 744-4400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
15
Stocks News & Analysis
stocks
ASX energy giant undervalued despite commissioning challenges
Near-term hurdles, long-term upside.
stocks
Undervalued ASX share upgrades guidance
Market share gains drive earnings upgrade despite a weak US housing backdrop.
stocks
ASX major bank drives strong quarterly profit
Profit momentum remains robust yet shares overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,112.00 | 79.70 | 0.88% |
| CAC 40 | 8,403.57 | 2.49 | -0.03% |
| DAX 40 | 25,311.43 | 49.60 | -0.20% |
| Dow JONES (US) | 52,210.08 | 262.83 | 0.51% |
| FTSE 100 | 10,816.47 | 34.72 | 0.32% |
| HKSE | 25,310.85 | 103.67 | 0.41% |
| NASDAQ | 24,932.08 | 43.74 | -0.18% |
| Nikkei 225 | 62,364.92 | 2,566.27 | -3.95% |
| NZX 50 Index | 13,861.93 | 11.24 | 0.08% |
| S&P 500 | 7,413.18 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,947.80 | 85.60 | 0.97% |
| SSE Composite Index | 3,813.31 | 44.93 | -1.16% |